Advanced Filters
noise

Additional Locations, New York Clinical Trials

A listing of Additional Locations, New York clinical trials actively recruiting patient volunteers.

Found 2,112 clinical trials
L Lynea Kaethler

The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis

Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and either inebilizumab (investigational agent) or placebo.

12 years of age All Phase 2
T Tejasvi Kaur Sahni

Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma

The goal of this clinical trial is to learn about how a combination of tazemetostat and venetoclax in people with relapsed/refractory Non-Hodgkin Lymphoma (R/R NHL). The main questions that this trial aims to answer are what is the best dose of venetoclax to give with tazemetostat to people with R/R …

18 years of age All Phase 1
E Eric Lowe, MD

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

The purpose of this study is to improve upon the TINI study treatment. The study will test the ability of a type of immunotherapy called blinatumomab to clear persistent leukemia. Blinatumomab targets CD19 which is located on the leukemia cells outer membrane.

- 1 years of age All Phase 1/2
J Jessica Bibeau, MA

Development and Testing of a Peer-Coaching Model for the Treatment of Eating Disorders

This project includes developing and testing a coaching approach during the treatment of eating disorders. It is expected that with the addition of support outside of regular treatment, caregivers will experience improvements in emotional taxation and patients will strengthen skills necessary for recovery. Twelve weeks of coaching will be incorporated …

12 - 18 years of age All Phase N/A
K Kenneth Hu

Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma

This will be a phase II single-arm clinical trial. The purpose of this study is to determine the feasibility of deescalating chemoradiation treatment based on mid-treatment tumor response determined by rapid nodal shrinkage and clearance of circulating HPV plasma tumor DNA . The primary objective of this study is to …

18 years of age All Phase 2
E Edwin Choy, M.D

Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.

18 - 99 years of age All Phase 3
S Sharad Goyal

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

This phase II trial studies the side effects of chemotherapy and intensity modulated radiation therapy in treating patients with low-risk HIV-associated anal cancer, and nivolumab after standard of care chemotherapy and radiation therapy in treating patients with high-risk HIV-associated anal cancer. Radiation therapy uses high energy x-rays to kill tumor …

18 years of age All Phase 2
D Deirdre Cohen, MD

Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer

A multi-institutional, single arm pilot study of antibiotics and pembrolizumab, following chemotherapy for the treatment of surgically resectable pancreatic cancer.

19 years of age All Phase 2
C Chinara Tate

Metabolic Diet for Relapse Prevention in Anorexia Nervosa

This is an interventional study that will test the safety, tolerability, and efficacy of the Metabolic Diet, which was designed as a treatment for women with anorexia nervosa to remain weight-stable after they have been restored from low weight. Participants will be adult women with anorexia nervosa who have been …

18 - 40 years of age Female Phase N/A
R Rachel Grisham, MD

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

To find out if combining pembrolizumab, bevacizumab (or an equivalent biosimilar drug), and low-dose cyclophosphamide can help control high-grade ovarian cancer that has MRD after treatment. The safety of this treatment combination will also be studied.

18 years of age Female Phase 2

Simplify language using AI